A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC.
Authors
Dean, Emma JWard, Timothy H
Pinilla, C
Houghten, R
Welsh, K
Makin, Guy W J
Ranson, Malcolm R
Dive, Caroline
Affiliation
Department of Clinical and Experimental Pharmacology, Paterson Institute for Cancer Research, University of Manchester, Wilmslow Road, Manchester M20 4BX, England, UK [2] Derek Crowther Unit, Christie Hospital NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, England, UK.Issue Date
2009-11-10
Metadata
Show full item recordAbstract
Background:Evasion of apoptosis contributes to the pathogenesis of solid tumours including non-small cell lung cancer (NSCLC). Malignant cells resist apoptosis through over-expression of inhibitor of apoptosis proteins (IAPs), such as X-linked IAP (XIAP).Methods:A phenylurea-based small molecule inhibitor of XIAP, XIAP antagonist compound (XAC) 1396-11, was investigated preclincally to determine its ability to sensitise to clinically relevant cytotoxics, potentially allowing dose reduction while maintaining therapeutic efficacy.Results:XIAP protein expression was detected in six NSCLC cell lines examined. The cytotoxicity of XAC 1396-11 against cultured NSCLC cell lines in vitro was concentration- and time-dependent in both short-term and clonogenic assays. XAC 1396-11-induced apoptosis was confirmed by PARP cleavage and characteristic nuclear morphology. XAC 1396-11 synergised with vinorelbine+/-cisplatin in H460 and A549 NSCLC cells. The mechanism of synergy was enhanced apoptosis, shown by increased cleavage of caspase-3 and PARP and by the reversal of synergy by a pan-caspase inhibitor. Synergy between XAC 1396-11 and vinorelbine was augmented by optimising drug scheduling with superior effects when XAC 1396-11 was administered before vinorelbine.Conclusion:These preclinical data suggest that XIAP inhibition in combination with vinorelbine holds potential as a therapeutic strategy in NSCLC.British Journal of Cancer advance online publication, 10 November 2009; doi:10.1038/sj.bjc.6605418 www.bjcancer.com.Citation
A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC. 2009: Br. J. CancerJournal
British Journal of CancerDOI
10.1038/sj.bjc.6605418PubMed ID
19904270Type
ArticleLanguage
enISSN
1532-1827ae974a485f413a2113503eed53cd6c53
10.1038/sj.bjc.6605418
Scopus Count
Related articles
- Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein.
- Authors: Karikari CA, Roy I, Tryggestad E, Feldmann G, Pinilla C, Welsh K, Reed JC, Armour EP, Wong J, Herman J, Rakheja D, Maitra A
- Issue date: 2007 Mar
- SMAC mimetic (JP1201) sensitizes non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-α-independent manner.
- Authors: Greer RM, Peyton M, Larsen JE, Girard L, Xie Y, Gazdar AF, Harran P, Wang L, Brekken RA, Wang X, Minna JD
- Issue date: 2011 Dec 15
- Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma.
- Authors: Carter CA, Chen C, Brink C, Vincent P, Maxuitenko YY, Gilbert KS, Waud WR, Zhang X
- Issue date: 2007 Feb
- XIAP-mediated protection of H460 lung cancer cells against cisplatin.
- Authors: Cheng YJ, Jiang HS, Hsu SL, Lin LC, Wu CL, Ghanta VK, Hsueh CM
- Issue date: 2010 Feb 10
- beta-Elemene, a novel plant-derived antineoplastic agent, increases cisplatin chemosensitivity of lung tumor cells by triggering apoptosis.
- Authors: Li QQ, Wang G, Zhang M, Cuff CF, Huang L, Reed E
- Issue date: 2009 Jul